[6, 30, 54] Evaluations of GHRH antagonists in prostate and lung cancers demonstrated their ability to modulate signaling pathways involved in cellular proliferation, survival, metastasis, and apoptosis.[23, 43, 44, 55] Among the affected pathways is the PI3K-AKT, which regulates inflammatory cytokines through NF-κβ.[43, 44, 56] Activation of the NF-κβ pathway by inflammatory cytokines has also been shown to enhance drug resistance in breast cancer. The gene discussed is AKT1; the disease is lung carcinoma.